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1. Introduction
Neuropathic pain is initiated by a primary lesion or 
dysfunction of the nervous system, which may be 
peripheral (peripheral nerve, plexus, nerve root) or 
central. The painful area within the territory of the 
injured nerve shows allodynia (hypersensitivity to 
normally non-painful stimuli), hyperalgesia and hy-
perpathia, which are hallmark signs of neuropathic 
pain [1]. There are different anatomical sites where 
lesions may cause neuropathic pain. The most usual 
locations are the peripheral nerves, the plexus, 
dorsal nerve roots, the spinal cord and brain [2].
Although a large number of studies have been 
done to reveal the mechanism of neuropathic pain 
but it is still not well established. Different patho-
logical phenomenon might be operating with nerve 
injury. Chronic nerve constriction leads to a marked 
demyelination and degeneration of both myeli-
nated A-fibers and unmyelinated C-fibers [3], but 
the damage of C-fibers is later and to a lesser ex-
tent compared with A-fibers after nerve ligatures. 
This model mimics some aspects of neuropathic pain 
in humans [4].
Activation of N-methyl-D-aspartic acid (NMDA) re-
ceptor is associated with increased intracellular Ca2+ 
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concentration and activation of Ca2+ sensitive pro-
tein kinase C, resulting in the production of nitric 
oxide (NO), which produces persistent enhancement 
of pain. The mechanism responsible for hyperalgesia 
in chronic pain is now believed to involve not only 
NO itself, but also the product of its reaction with 
superoxide radicals, the peroxynitrites [5].
Several experimental models of peripheral 
mononeuropathy in rats were developed wherein 
chronic constriction injury [6] or partial lesion [7] 
of sciatic nerve or its root [8] was performed. 
The allodynia and hyperalgesia that develop there-
after have led to considerable advances in under-
standing neuropathic pain resulting from nerve 
injury. Changes were observed in pain behavior with 
a peak occurring at 2−4 weeks post injury [9].
Despite intensive research on the neurobiological 
mechanism of chronic pain, this therapeutic area 
remains one of the least satisfactorily managed using 
current medications. Effective therapy for this type 
of pain is lacking, and the underlying mechanisms 
are poorly understood [10]. Chronic pain is often re-
fractory to treatment with conventional analgesics 
such as opiates and non-steroidal anti-inflammatory 
drugs [11,12]. The use of opioids in neuropathic pain 
is controversial because of their limited efficacy in 
this pain state as compared to other pain states. NMDA 
receptor antagonists, adenosine analogues, neuronal 
specific Ca2+ channel blockers and NO modulators 
are among the pharmacological tools that are being 
studied to find out new treatment strategies [1].
Several lines of evidence indicate that the NMDA 
receptor is involved in the induction and mainte-
nance of hypersensitivity states associated with 
chronic pain, including neuropathic pain. NMDA re-
ceptor antagonists block pain transmission in dorsal 
horn spinal neurons [13,14] and reduce pain-related 
behavior in neuropathic animal models [15,16]. 
The present study is therefore aimed at under-
standing the role of NO and its interaction with 
NMDA in chronic constriction injury induced neu-
ropathy in rats.
2.  Materials and Methods
2.1.  Animals and surgery
Male albino mice weighing 23 ± 2 g were used in all 
experiments. The animals were housed in groups of 
six under conditions of constant temperature (22−
25ºC) and a light-controlled room (12-hour light/dark 
cycle) and with free access to food and water. The 
surgical procedure for nerve ligation was performed 
as follows. Unilateral peripheral mononeuropathy 
was produced on the right hind limb, based on the 
method of Seltzer et al [7], except that the animals 
were anesthetized with ketamine (40 mg/kg) and xy-
lazine (10 mg/kg) and a copper wire was used for li-
gation. The animal’s right sciatic nerve was exposed, 
and a 2−3 mm long nerve segment was then dis-
sected. Only one ligature with fine metal wire was 
made around the dissected nerve. All the control 
animals were sham-operated.
2.2.  Analgesic measurement
Pain sensitivity was assessed using the hot-plate test 
as described by Eddy and Liembach [17], with minor 
modifications. Briefly, the animal was placed on a 
circular surface (diameter 19 cm) maintained at 
55 ± 0.2ºC and surrounded by a Plexiglass wall (12 cm 
high). The apparatus (Harvard, England, UK) was 
equipped with a timer and a thermocoupler to main-
tain a constant temperature. Licking the forepaws, 
lifting hindpaws or jumping from the surface was 
used as the end point for the determination of re-
sponse latencies [18]. Failure to respond by 45 sec-
onds resulted in the termination of the test (cut-off). 
Fourteen days after nerve ligation of animals, anal-
gesia achieved following drug administration was 
measured.
2.3.  Drugs
Chemicals used were dextromethorphan (Alhavi 
Pharmaceutical Co., Tehran, Iran), L-NAME (Sigma-
Aldrich, Munich, Germany), saline, ketamine 5%, 
xylazine (Chanelle Pharmaceuticals Manufacturing 
Ltd., Loughrea, Ireland). All drugs were dissolved 
in saline and were injected intraperitoneally (ip).
2.4.  Statistical analysis
Data was analyzed using analysis of variance followed 
by Newman-Keuls test. Unpaired t test was used 
for comparison between control animals (sham-
operated) and the sciatic nerve ligated group. 
Differences between means were considered sta-
tistically significant if p < 0.05. Data is represented 
as the mean ± SEM for six mice.
3. Results
Significant allodynia and hyperalgesia were observed 
following the comparison between control animals 
(sham-operated) and the sciatic nerve ligated group, 
14 days after surgery (Figure 1).
Administration of dextromethorphan (ip) 10, 30 
and 45 mg/kg to ligated mice induced significant 
analgesia as compared with saline treated animals. 
The analgesic response was dose-dependent and a 
greater response was obtained using 45 mg/kg of 
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dextromethorphan (Figure 2). Administration of 
L-NAME (ip) 10, 50 and 100 mg/kg to ligated mice 
caused a significant dose-dependent analgesia when 
compared with saline treated animals (Figure 3). 
Effects of L-NAME 10 mg/kg and 50 mg/kg on the 
effects of different doses of dextromethorphan 
after 30, 60 and 90 minutes of administration did 
not show significant differences to dextromethor-
phan only treated groups. Latency periods after 
administration of 100 mg/kg of L-NAME to mice 
treated with dextromethorphan (ip) 10, 30 and 
45 mg/kg in 30, 60 and 90 minutes, increased sig-
nificantly in comparison with dextromethorphan 
only treated groups (Figure 4).
4. Discussion
The symptoms of neuropathic pain are often in-
tractable because they are poorly relieved by con-
ventional analgesics [19−21]. Traumatic nerve 
injury can lead to the development of hyperalge-
sia or/and allodynia. An increase in the afferent 
impulse rate from the damaged nerve area en-
hances the activity of spinal dorsal horn neurons, 
producing pain [4]. Activation of NMDA receptors 
in the spinal dorsal horn neurons is critical to the 
development and maintenance of the hyperalgesia 
induced by nerve injury [22−24].
Our study showed that dextromethorphan, an 
NMDA antagonist, has analgesic properties. This 
result is in agreement with previous studies using 
ketamine, a NMDA antagonist, which has been 
shown to be effective in reducing various types of 
neuropathic pain symptoms in patients [25−28].
The activation of neuronal firing by NMDA re-
ceptors leads to an increase in intracellular calcium 
levels [29,30]. Dextromethorphan has been shown 
to reduce and regulate the influx of intracellular 
calcium through NMDA receptor-gated channels [31]. 
This action antagonizes the effects of excitatory 
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Figure 1 Latency response of sham-operated A group 
in comparison with sciatic nerve ligated B group (n = 6, 
data shown as mean ± SEM). *p < 0.05.
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Figure 2  Latency response of dextromethorphan (Dex) 
treated group in comparison with saline treated group 
(n = 6, data shown as mean ± SEM). *p < 0.05. NS = normal 
saline treated group.
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Figure 3 Latency response of the L-nitro-arginine methyl 
ester (L-NAME) treated group in comparison with the saline 
treated group (n = 6, mean ± SEM). *p < 0.05. NS = normal 
saline treated group.
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Figure 4  Effect of L-nitro-arginine methyl ester (L-NAME) 
on the latency response of dextromethorphan (Dex) in 
comparison with the Dex-only treated group (n = 6, mean ± 
SEM). *p < 0.05.
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amino acids and reduces the release of various 
peptides, such as glutamate and aspartate, and ul-
timately may lead to an overall reduction of pain 
sensation [32].
Glutamate induces thermal hyperalgesia through 
the activation of NMDA receptors and subsequent 
production of nitric oxide [4]. As we observed, L-NAME 
had analgesic effects in sciatic nerve ligated mice. 
NO is highly involved in analgesic processing in the 
central nervous system, at both the spinal and su-
praspinal levels. Previous studies have demon-
strated that intrathecal injection of L-arginine and 
NO-releasing compounds produced hyperalgesia in 
the tail flick test and formalin pain model [33−35], 
illustrating the involvement of NO in the pain path-
ways. Following the co-administration of dex-
tromethorphan and L-NAME, an increased latency 
period and more analgesia were observed.
The activation of NMDA receptors in the central 
nervous system initiates an influx of Ca2+, inducing 
Ca-dependent intracellular processes [36,37]. Nitric 
oxide synthase is stimulate in a Ca2+-dependent 
manner by the activation of NMDA receptors and is 
responsible for the synthesis of NO from L-arginine 
[38,39]. In addition, NO has also been shown to 
enhance the release of excitatory amino acids 
[40−43]. Furthermore, certain states of pathologi-
cal pain are reversibly blocked by the administra-
tion of nitric oxide synthase inhibitors [44] and 
NMDA receptor antagonists [45,46]. In conclusion, 
these observations support the idea that NMDA/NO 
pathways play an important role in the development 
of such sciatic nerve ligated-evoked pathological 
pain conditions as allodynia, hyperalgesia and phan-
tom pain. Further studies are needed to reveal the 
role of NO and NMDA and their related mechanisms 
in such pain conditions.
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